BridgeBio Pharma (BBIO) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 115.2% versus a gain of 22.6%. Over five years, PTGX leads with a +355.0% price change compared with +38.6% for BBIO. BridgeBio Pharma is the larger company by market cap ($12.75 billion vs $9.17 billion), about 1.4 times the size.
BridgeBio Pharma converts more of its revenue into profit, with a net margin of -146.0% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | PTGX |
|---|---|---|
| Share price | $65.23 | $141.65 |
| Market cap | $12.75B | $9.17B |
| 1-day change | -1.91% | +0.52% |
| YTD return | -13.06% | +61.35% |
| 1-year return | +22.65% | +115.24% |
| 5-year return | +38.60% | +355.02% |
| P/E ratio (TTM) | — | 137.52 |
| EPS (TTM) | $-3.56 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $46.02M |
| Revenue growth (YoY) | +126.26% | -89.41% |
| Net income (latest FY) | $-732.94M | $-130.15M |
| Gross margin | 95.82% | — |
| Operating margin | -104.25% | -343.63% |
| Net margin | -145.98% | -282.83% |
| 52-week high | $93.42 | $160.81 |
| 52-week low | $52.75 | $65.56 |
| Distance from 52-week high | -30.17% | -11.91% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +67.18% | +23.33% |
| Average volume | 2.75M | 632.64K |
| Shares outstanding | 195.49M | 64.71M |
| Employees | 999 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed BBIO by 92.6 percentage points over the past year.
- BridgeBio Pharma is more profitable, keeping -146.0 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs -89.41%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
BBIO vs PTGX FAQ
Which is bigger, BridgeBio Pharma or Protagonist Therapeutics?
BridgeBio Pharma (BBIO) is larger, with a market capitalization of $12.75B compared with $9.17B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, BBIO or PTGX?
PTGX returned +115.24% over the past 12 months, compared with +22.65% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.